The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.
TIMI Study Group
https://pubmed.ncbi.nlm.nih.gov/4038784Completed
Phase 3
Age: 18Years - 75Years
All Genders
ID00000505
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2016-03-16
N/A
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).
CONDITIONS
Official Title
Thrombolysis in Myocardial Infarction (TIMI)
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
Men and women under age 76. Patients had acute myocardial infarction.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
RANDOMIZED
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial.
L D Hillis, J Borer, E Braunwald...
https://pubmed.ncbi.nlm.nih.gov/4045046Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
D O Williams, J Borer, E Braunwald...
https://pubmed.ncbi.nlm.nih.gov/3080261Announcement of protocol change in thrombolysis in myocardial infarction trial.
E Braunwald, G L Knatterud, E R Passamani...
https://pubmed.ncbi.nlm.nih.gov/3100602The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial.
F H Sheehan, E Braunwald, P Canner...
https://pubmed.ncbi.nlm.nih.gov/3103950Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
J H Chesebro, G Knatterud, R Roberts...
https://pubmed.ncbi.nlm.nih.gov/3109764Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
H S Mueller, A K Rao, S A Forman
https://pubmed.ncbi.nlm.nih.gov/3114349Patient recruitment experience in the Thrombolysis in Myocardial Infarction Trial.
G L Knatterud, S A Forman
https://pubmed.ncbi.nlm.nih.gov/3126024Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial.
D O Williams, N A Ruocco, S Forman
https://pubmed.ncbi.nlm.nih.gov/2959715The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.
E Passamani, M Hodges, M Herman...
https://pubmed.ncbi.nlm.nih.gov/2889758